We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$167B
$72.2M 1.23%
1,069,200
+991,400
+1,274% +$65.2M
MRNA icon
27
Moderna
MRNA
$24.5B
$69.2M 1.18%
+4,724,246
New +$101M
HUM icon
28
Humana
HUM
$48B
$64M 1.09%
241,212
+88,735
+58% +$22.5M
MYOK
29
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$63.4M 1.08%
+1,264,913
New +$61.6M
BSX icon
30
Boston Scientific
BSX
$65.4B
$59.3M 1.01%
1,380,782
+233,295
+20% +$8.97M
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$56.6M 0.97%
711,803
+694,576
+4,032% +$62.2M
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$51.9M 0.89%
+1,369,604
New +$52.6M
DHR icon
33
Danaher
DHR
$144B
$50.1M 0.86%
395,587
+10,055
+3% +$1.19M
ALDR
34
DELISTED
Alder Biopharmaceuticals
ALDR
$48.5M 0.83%
4,118,806
+2,832,058
+220% +$34.3M
UNH icon
35
UnitedHealth
UNH
$387B
$47.4M 0.81%
194,394
+61,557
+46% +$14.8M
JAZZ icon
36
Jazz Pharmaceuticals
JAZZ
$15.5B
$47.4M 0.81%
332,173
+64,735
+24% +$8.7M
WVE icon
37
Wave Life Sciences
WVE
$1.12B
$39.5M 0.67%
+1,515,002
New +$42.5M
SGMO
38
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$39.3M 0.67%
+3,650,000
New +$38.8M
BMY icon
39
Bristol-Myers Squibb
BMY
$124B
$38.8M 0.66%
855,609
+159,785
+23% +$7.44M
CRSP icon
40
CRISPR Therapeutics
CRSP
$4.71B
$38.2M 0.65%
+810,462
New +$32.4M
BDX icon
41
Becton Dickinson
BDX
$43.6B
$37.7M 0.64%
153,434
+21,238
+16% +$4.93M
MYOV
42
DELISTED
Myovant Sciences Ltd.
MYOV
$35.4M 0.6%
+3,910,109
New +$58.3M
CNC icon
43
Centene
CNC
$32.8B
$35.4M 0.6%
674,525
+499,537
+285% +$27M
ABMD
44
DELISTED
Abiomed Inc
ABMD
$35.1M 0.6%
134,682
+75,293
+127% +$20M
CI icon
45
Cigna
CI
$74.5B
$33.2M 0.57%
210,754
+45,097
+27% +$7.07M
SYK icon
46
Stryker
SYK
$123B
$32.7M 0.56%
159,163
+10,263
+7% +$1.96M
EW icon
47
Edwards Lifesciences
EW
$49.4B
$32.1M 0.55%
521,898
+36,162
+7% +$2.19M
SRRK icon
48
Scholar Rock
SRRK
$6.33B
$31M 0.53%
+1,951,839
New +$36.2M
QGEN icon
49
Qiagen
QGEN
$8.49B
$30.2M 0.52%
702,117
+120,069
+21% +$4.97M
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$29.1M 0.5%
+2,245,500
New +$28.8M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.